Peptide Comparison
LarazotidevsThymosin Beta-4
Restore your intestinal barrier and protect against gluten damage
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Larazotide
250 mcg–1000 mcg mcg
Thymosin Beta-4
2–5 mg
Frequency
Larazotide
Once daily
Thymosin Beta-4
Twice weekly
Administration
Larazotide
Oral (capsule or tablet)
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Larazotide
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
Larazotide
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Larazotide
Strong human trials (Phase 3 or FDA approved)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Intestinal Barrier Protection
Celiac Disease Management
Safety & Tolerability
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Larazotide
Molecular Formula
C34H59N9O12
Molecular Weight
785.9 g/mol
Half-Life
Unknown - acts primarily as local intestinal barrier regulator rather than systemic drug
Bioavailability
Orally administered; acts locally on intestinal epithelium with minimal systemic absorption
CAS Number
206899-25-6
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
Larazotide
Managing celiac disease symptoms despite strict gluten avoidance
Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing accidental gluten exposure damage
Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring digestive comfort and nutrient absorption
Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting intestinal healing and barrier function
Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Larazotide
Common
- Headache
- Nausea
- Abdominal Cramping
- Fatigue
Uncommon
- Transient Diarrhea
Serious
- Allergic Reaction
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Larazotide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Larazotide (ALX-0061, AT-1001) is a synthetic tight-junction regulator that improved intestinal barrier function in Phase 2 celiac disease trials with favorable safety. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.
Contraindications
- xKnown hypersensitivity to larazotide or any component
- xSevere gastrointestinal obstruction
- xActive untreated infections (may require monitoring)
- xPregnancy and breastfeeding (limited safety data)
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Larazotide if...
- Managing celiac disease symptoms despite strict gluten avoidance
- Reducing accidental gluten exposure damage
- Restoring digestive comfort and nutrient absorption
- Supporting intestinal healing and barrier function
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation